“I think the key [is to not] get rid of financial incentives. I don't think that's possible. [Rather, we should] align financial incentives [so] that [we] can promote what is best for patients,” says Lillian Y. Lai, MD.
In this video, Lillian Y. Lai, MD, discusses the findings of the Urology Practice study, “Commercial prices for prostatectomy and treatment among younger, privately insured men with prostate cancer.” Lai is a Society of Urologic Oncology fellow at the University of Michigan, Ann Arbor.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.